

Indoco Remedies receives US FDA nod for Lacosamide Oral Solution

Agencies
Mumbai

Indoco Remedies Ltd announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market, a generic equivalent to the reference listed drug (RLD), Vimpat Oral Solution, 10 mg/mL, of UCB, Inc. (UCB), from USFDA.

Lacosamide Oral Solution USP, 10 mg/mL, is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10

mg/mL, of UCB, Inc. (UCB) and is manufactured in Verna.

Lacosamide Oral solution is used to treat partial onset seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy who are at least 4 years old.

Commenting on the achievement, Aditi Panandikar, Managing Director said, "We are excited about the ANDA approval for Lacosamide Oral Solution USP, 10 mg/ml. This approval further reinforces our commitment to delivering high-quality healthcare to patients worldwide."